Biomica is a clinical-stage biopharmaceutical company dedicated to developing innovative microbiome-based therapeutics for the treatment of cancer, immune-mediated, and infectious diseases. Synergizing proprietary big data and computational capabilities, Biomica develops best-in-class therapeutics to address high-value, unmet medical needs.
Our unique approach is focused on understanding the functional elements of the microbiome. This enables us to select a minimal number of desired microbial candidates, thereby maximizing beneficial effects while minimizing potential adverse effects through carefully curated consortia.
Our drug candidates have been identified and designed using PRISM, a proprietary cutting-edge computational platform that integrates advanced AI capabilities, ‘Big Data’, and a comprehensive proprietary database. Through metagenomics sequencing, Biomica gains deeper insights into the microbiome, employing high-resolution taxonomy and functional profiling of the human microbiome. These insights enable us to develop novel solutions for complex host-microbiome interrelations and make clinically relevant predictions.
Biomica’s CEO, Dr. Elran Haber, is heading to Brussels this week for the Microbiome Times Partnering Forum – a key event for advancing microbiome-based therapeutics through strategic partnerships. More info & registration: www.microbiomeforum.com
Dr. Elran Haber, Biomica’s CEO, will attend MIXiii Health-Tech.IL 2025 on March 4-5 at ICC Jerusalem. This leading Israeli health-tech conference unites industry leaders, startups, and investors to explore innovations in personalized medicine, AI-driven drug development, cancer treatment, and more. More info & registration: www.mixiii.com
We’re excited to join Startup Nation Central’s Israel Health Tech delegation to the U.S. Our CEO, Dr. Elran Haber, will proudly represent Biomica on this journey.
